D. E. Shaw & Co., Inc. Supernus Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

$114 Billion
Q1 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 130,366 shares of SUPN stock, worth $3.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

130,366

Previous 129,153 0.94%

Holding current value

$3.39 Million

Previous $3.74 Million 18.97%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$27.11 - $35.17 $32,884 - $42,661	1,213 Added 0.94%	130,366 $4.45 Million
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $2.37 Million - $3.09 Million	104,130 Added 416.14%	129,153 $3.74 Million
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $14,419 - $17,211	523 Added 2.13%	25,023 $689,000
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $142,850 - $184,974	-4,776 Reduced 16.31%	24,500 $736,000
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $2,689 - $3,236	-77 Reduced 0.26%	29,276 $1.06 Million

Q4 2022 Feb 14, 2023	BUY	$31.09 - $37.88 $66,936 - $81,555	2,153 Added 7.92%	29,353 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $319,569 - $393,050	11,100 Added 68.94%	27,200 $921,000
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $211,758 - $286,330	8,360 Added 108.01%	16,100 $466,000
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $220,667 - $254,646	7,740 New	7,740 $250,000
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $233,587 - $311,482	-9,923 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $129,351 - $160,672	-4,841 Reduced 32.79%	9,923 $306,000
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $160,428 - $208,922	-6,643 Reduced 31.03%	14,764 $387,000
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $2.07 Million - $3.02 Million	-117,117 Reduced 84.55%	21,407 $539,000
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $1.88 Million - $2.34 Million	-93,251 Reduced 40.23%	138,524 $2.89 Million
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $56,345 - $82,062	3,297 Added 1.44%	231,775 $5.51 Million
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $1.01 Million - $1.72 Million	69,630 Added 43.83%	228,478 $4.11 Million
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $2.9 Million - $4.25 Million	145,748 Added 1112.58%	158,848 $3.77 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $333,657 - $437,146	13,100 New	13,100 $360,000
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $824,948 - $1.07 Million	-27,535 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $831,276 - $1.07 Million	-25,367 Reduced 47.95%	27,535 $965,000
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $1.63 Million - $2.62 Million	52,902 New	52,902 $1.76 Million
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $326,340 - $442,890	-7,400 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$37.15 - $46.9 $187,867 - $237,173	-5,057 Reduced 40.6%	7,400 $339,000
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $14,378 - $16,827	-395 Reduced 3.07%	12,457 $496,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $472,311 - $638,101	12,852	12,852 $514,000

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.39B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account